# SURMOUNT-MAINTAIN: Full-Dose Tirzepatide, 5 mg or Placebo After 60 Weeks

In SURMOUNT-MAINTAIN, weight was 21.9% below baseline on full-dose tirzepatide, 16.6% at 5 mg and 9.9% on placebo, with rescue tirzepatide given to 8%, 25% and 67%, respectively.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/two-thirds-on-placebo-needed-rescuing
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# SURMOUNT-MAINTAIN: Full-Dose Tirzepatide, 5 mg or Placebo After 60 Weeks

After 60 weeks on tirzepatide, 378 adults were randomized to continue their maximum tolerated dose, drop to 5 mg or switch to placebo. Rescue tirzepatide was given to 8%, 25% and 67%, respectively, in the rescue analysis.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20267 min readUpdated November 2026

At week 112 · loss from baseline · received rescue · stayed on full dose · 21.9% · 8% · dropped to 5 mg · 16.6% · 25% · switched to placebo · 9.9% · 67% · 60 of 90 in the placebo analysis received rescue tirzepatide.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   After a 60-week lead-in, 378 adults were randomized to stay at their maximum tolerated dose of tirzepatide, reduce to 5 mg, or switch to placebo.
-   At week 112, estimated weight loss from the start of the trial was 21.9%, 16.6%, and 9.9%, respectively.
-   Rescue tirzepatide was given to 11 of 138 (8%), 35 of 142 (25%), and 60 of 90 (67%), respectively, in the analysis reporting rescue use.

## Who entered the maintenance phase?

Of the 441 adults who started open-label tirzepatide, 378 qualified for randomization at week 60. They had lost at least 5% of baseline weight and tolerated at least 10 mg. The trial assigned 140 to continue their maximum tolerated dose of 10 mg or 15 mg, 144 to reduce to 5 mg, and 94 to switch to placebo for another 52 weeks.[\[1\]](https://buythisglp.com/research/two-thirds-on-placebo-needed-rescuing#ref-1)

The evidence on [lower-dose GLP-1 maintenance](https://buythisglp.com/research/can-you-lower-your-glp1-dose-to-maintain) depends on which patients enter a study. SURMOUNT-MAINTAIN selected adults who had already lost weight and tolerated a higher dose, so the results apply most directly to patients who meet those conditions.

## Weight change and rescue treatment

At week 112, the model estimated weight loss from the original baseline at 21.9% (95% CI 20.3% to 23.5%) on the maximum tolerated dose, 16.6% (95% CI 15.1% to 18.0%) on 5 mg, and 9.9% (95% CI 8.8% to 11.1%) on placebo. Both tirzepatide groups had greater weight loss from baseline than placebo.[\[1\]](https://buythisglp.com/research/two-thirds-on-placebo-needed-rescuing#ref-1)

From week 84, 24 weeks after randomization, the protocol allowed rescue tirzepatide if participants regained more than half the weight they had lost. In the rescue analysis, 11 of 138 (8%) at the maximum tolerated dose, 35 of 142 (25%) at 5 mg, and 60 of 90 (67%) on placebo received it.[\[1\]](https://buythisglp.com/research/two-thirds-on-placebo-needed-rescuing#ref-1)

How the analysis handled rescue treatment

When comparing [weight regain after stopping medication](https://buythisglp.com/research/how-much-weight-do-you-regain-after-stopping) across studies, check whether participants could restart treatment. The main SURMOUNT-MAINTAIN analysis kept participants in their assigned group when they received rescue. It assumed that after rescue began they would have gained no further benefit from their assigned treatment.[\[1\]](https://buythisglp.com/research/two-thirds-on-placebo-needed-rescuing#ref-1)

## Safety and funding

Gastrointestinal symptoms were the most common adverse events with tirzepatide and occurred mainly during dose escalation. Eli Lilly funded the trial and took part in the design, data collection, analysis, and preparation of the report.[\[1\]](https://buythisglp.com/research/two-thirds-on-placebo-needed-rescuing#ref-1)

## Frequently asked

What happens if I stop after losing weight?

In the trial’s rescue analysis, 60 of 90 people switched to placebo received rescue tirzepatide, compared with 11 of 138 who continued their maximum tolerated dose.

Can I drop to a lower dose instead?

In this selected group, estimated weight loss from the original baseline was 16.6% on 5 mg, 21.9% at the maximum tolerated dose, and 9.9% on placebo at week 112. Discuss maintenance options with your prescriber.

Does this apply to everyone?

To enter the randomized maintenance phase, adults had to lose at least 5% of baseline weight during the lead-in and tolerate at least 10 mg of tirzepatide.

## Sources

1.  \[1\] Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, et al. (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial The Lancet. [PMID 42119587](https://www.sciencedirect.com/science/article/pii/S0140673626006562)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
